echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Shufang Pharmaceutical and Heyu Pharmaceutical reached an exclusive development agreement for the new drug ABSK021 in Greater China

    Shufang Pharmaceutical and Heyu Pharmaceutical reached an exclusive development agreement for the new drug ABSK021 in Greater China

    • Last Update: 2021-08-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Shufang (Shanghai) Pharmaceutical, a subsidiary of Shufang Pharmaceutical, and Shanghai Heyu Biopharmaceutical have reached an exclusive licensing agreement to jointly develop the innovative drug ABSK021 for the application of indications in the field of rare diseases of the nervous system in the Greater China region


    According to the exclusive license agreement, Sufang Pharmaceutical will obtain the exclusive rights to develop, produce, and commercialize ABSK021 in Mainland China, Hong Kong and Macau Special Administrative Regions (hereinafter collectively referred to as the "authorized regions").


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.